Stock ORCHPHARMA ORCHID PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Orchid Pharma Limited

Equities

ORCHPHARMA

INE191A01027

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:55 2024-07-12 am EDT 		5-day change 1st Jan Change
1,130 INR -1.97% Intraday chart for Orchid Pharma Limited -1.21% +58.56%
Jun. 28 Orchid Pharma Partners with Cipla to Launch Antibiotic Cefepime- Enmetazobactam in India CI
Jun. 06 Orchid Pharma Gets Indian Regulator's Nod for Enmetazobactam MT

Valuation

Fiscal Period: March 2024 2025 2026
Capitalization 1 57,300 - -
Enterprise Value (EV) 1 51,673 55,652 55,253
P/E ratio 72.1 x 38.3 x 27.4 x
Yield - - -
Capitalization / Revenue 6.47 x 5.57 x 3.86 x
EV / Revenue 6.31 x 5.41 x 3.72 x
EV / EBITDA 46.7 x 32.5 x 22.1 x
EV / FCF 84.5 x -81.3 x -29.4 x
FCF Yield 1.18% -1.23% -3.4%
Price to Book 4.53 x 4.35 x 4.06 x
Nbr of stocks (in thousands) 50,719 - -
Reference price 2 1,130 1,130 1,130
Announcement Date 5/23/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2023 2024 2025 2026
Net sales 1 - 8,194 10,284 14,842
EBITDA 1 - 1,107 1,715 2,499
EBIT 1 - 774.4 1,298 1,950
Operating Margin - 9.45% 12.63% 13.14%
Earnings before Tax (EBT) 1 - 919.5 1,491 2,235
Net income 1 463.2 921.7 1,486 2,172
Net margin - 11.25% 14.45% 14.63%
EPS 2 - 14.49 29.50 41.23
Free Cash Flow 1 - 611.8 -684.5 -1,880
FCF margin - 7.47% -6.66% -12.67%
FCF Conversion (EBITDA) - 55.28% - -
FCF Conversion (Net income) - 66.38% - -
Dividend per Share - - - -
Announcement Date 5/10/23 5/23/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2024 Q3 2024 Q4 2025 Q1
Net sales 1 2,098 2,524 2,260
EBITDA 1 265.5 404 318.5
EBIT - - -
Operating Margin - - -
Earnings before Tax (EBT) - - -
Net income 1 201 - 349
Net margin 9.58% - 15.45%
EPS 2 4.000 - 6.900
Dividend per Share - - -
Announcement Date - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2023 2024 2025 2026
Net Debt 1 - - - -
Net Cash position 1 - 1,321 1,648 2,047
Leverage (Debt/EBITDA) - - - -
Free Cash Flow 1 - 612 -685 -1,881
ROE (net income / shareholders' equity) - 9.92% 11.7% 14.8%
ROA (Net income/ Total Assets) - - - -
Assets 1 - - - -
Book Value Per Share 2 - 231.0 260.0 279.0
Cash Flow per Share - - - -
Capex 1 - 648 2,723 4,378
Capex / Sales - 7.91% 26.48% 29.5%
Announcement Date 5/10/23 5/23/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,130 INR
Average target price
1,252 INR
Spread / Average Target
+10.85%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ORCHID PHARMA LIMITED Stock Orchid Pharma Limited
+58.56% 686M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.66% 854B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 636B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.16% 324B
ABBVIE INC. Stock AbbVie Inc.
+9.87% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.66% 247B
ROCHE HOLDING AG Stock Roche Holding AG
+4.21% 230B
NOVARTIS AG Stock Novartis AG
+17.90% 228B
AMGEN INC. Stock Amgen Inc.
+14.86% 177B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ORCHPHARMA Stock
  4. Financials Orchid Pharma Limited